Healthcare global

Healthcare is a fast-growing market that is particularly interesting for investors. A key growth driver is an aging society and the diseases and conditions that afflict the elderly. Meanwhile the growing Westernization of modern lifestyles has long been a reality and will become even more apparent in the decades to come. This trend explains the rise of many of today's chronic diseases. There are now more than 400 million people with diabetes worldwide, for example, and the trend is still pointing up. Innovative drugs and new forms of treatment are needed to contain the sharply rising cost of healthcare.

Many investors still think of a classic pharmaceutical company when they hear the word “healthcare”, but the healthcare sector actually offers a much wider selection of investment opportunities than just pharma. The professionals at Bellevue Asset Management actively cover and capture the most promising of these opportunities.

Our expertise

Our Healthcare Team consists of an interdisciplinary mix of experts with many years of experience in the fields of biotechnology, medical technology and generics. Many of our experts are graduate biochemists or natural scientists with further economic training. The experienced team analyses a global universe of 600 listed healthcare companies by means of fundamental analysis using various quantitative and qualitative parameters. An important part of the research is regular company visits and participation in technical and financial conferences.

Team BB Adamant Healthcare (Funds & Mandates)

Cyrill  Zimmermann
Dr. Cyrill Zimmermann, Head
  • Since 2015 Head Healthcare Funds & Mandates, Member of the Executive Board
  • 2001-2014 Co-founder and CEO of Adamant Biomedical Investment AG
  • 1996-2000 Member of the Management Team BB Medtech at Bellevue Asset Management AG
  • 1993-96 Advisor for institutional clients and former assistant to the Executive Management at Credit Suisse
  • Dr.oec.publ. (University of Zurich)
Oliver Kubli
Oliver Kubli, CFA, Portfolio Manager
  • Since 2015 Managing Director, Head Portfolio Management Healthcare Funds & Mandates
  • 2008-2014 Member of the Management Team and Head Portfolio Management at Adamant Biomedical Investment AG
  • 2000-2007 Senior Portfolio Manager at Zürcher Kantonalbank
  • Bachelor of Business Administration, University of Applied Sciences, Winterthur, CFA
Remo Krauer
Remo Krauer, CIIA, Portfolio Manager
  • Since 2018 Senior Portfolio Manager Healthcare Funds & Mandates
  • 2016 -2018 Head Portfolio Construction, Discretionary Mandates at Zürcher Kantonalbank
  • 2005 – 2016 Senior Portfoliomanager at Zürcher Kantonalbank
  • Bachelor of Business Administration, University of Applied Sciences, Winterthur, CIIA
Samuel Stursberg
Samuel Stursberg, CFA, Portfolio Manager
  • Since 2015 Head Research Healthcare Funds & Mandates
  • 2007-2014 Head Research at Adamant Biomedical Investment AG
  • 2005-2007 Stock analysis medtech and biotech at Bank Sarasin
  • 2001-2005 Sustainable Asset Management, stock analysis in healthcare
  • M.Sc University of Basel, MBA HSG, CFA
Christian Lach
Dr. Christian Lach, Portfolio Manager
  • Since 2015 Senior Portfolio Manager Healthcare Funds & Mandates
  • 2008-2014 Senior Portfolio Manager in Biotech at Adamant Biomedical Investment AG
  • 2001-2008 Member of the Management Teams BB Biotech and BB Medtech at Bellevue Asset Management AG
  • Dr. oec. HSG, dipl. natw. ETH
Hanns Frohnmeyer
Dr. Hanns Frohnmeyer, Portfolio Manager
  • Since 2017 Senior Portfolio Manager Healthcare Funds & Mandates
  • 2011 – 2015 Aeris Capital, Executive Director Life Science
  • 2001 – 2011 LBBW, Head of Life Science Analyst Team
  • 1994 – 2001University Freiburg, Assistant professor (Molecular biology)
Stefan  Blum
Stefan Blum, CEFA, Portfolio Manager
  • Since 2008 with Bellevue Asset Management as lead portfolio manager of the BB Adamant Medtech & Services (Lux) Fund
  • 2004 - 2008 Sonova, head investor relations
  • 2000 - 2004 Obtree Technologies Inc., finance and investor relations
  • 1996 - 2000 Bank Sarasin, medtech analyst
  • Master’s degree in Business Economics, University of St. Gallen (HSG), CEFA charterholder
Marcel  Fritsch
Marcel Fritsch, Portfolio Manager
  • Since 2008 with Bellevue Asset Management as portfolio manager of the BB Adamant Medtech & Services (Lux) Fund
  • 2004 - 2008 Deloitte & Touche LLP, business consultant with focus on the medtech and pharmaceutical sectors
  • Master’s degree in Business Economics, University of St. Gallen (HSG)
Marvin Ng
Marvin Ng, MBA, Consultant
  • Consultant Bellevue Asset Management in Asia
  • Since 2002 DN Venture Partners, Singapore/Germany, Director and consultant to life sciences organisations on business development in Asia
  • Since 2002 Greener Grass Communications, Singapore, Director and consultant to technology companies on public relations matters
  • First Class Honours Degree in Microbiology, University of British Columbia (Canada), Masters in Business Administration, Simon Fraser University (Canada)
Michael  Mullen
Prof. Michael Mullen, CFA, Consultant
  • Consultant Bellevue Asset Management AG in the United States
  • Since 2005 Tarvos Capital Management, LLC, Boston / Basel, Managing Director and founder
  • 1999-2005 President of Bellevue’s U.S. research operation, Co-manager of lead products: BB Biotech and BB Medtech
  • B.S. from Fordham University in Accounting and Finance
  • MBA from Indiana University Graduate School of Business
  • CFA, member of the CFA Institute
Zahide Donat
Zahide Donat, Portfolio Manager
  • Since 2015 Portfolio Manager
  • 2014-2015 Credit Suisse AG, Banking Operations Specialist in Fixed Income
  • 2010-2013 Migros Bank AG, Relationship Manager
  • Bachelor of Science ZFH in Business Administration (Focus Banking and Finance)
Sandra Muino
Sandra Muino, Operations & Finance
  • Since 2015 Operations& Finance at Bellevue Asset Management
  • 2002-2014 Compliance Officer Adamant Biomedical Investments AG
  • Professional Bachelor in Business Administration
Christina Wirz
Christina Wirz, Office Manager/Assistant
  • Since 2015 at Bellevue Asset Management
  • 2012-2015 Bank Vontobel, Administration team Investment Banking
  • 1999-2012 UBS AG, Team Global Wealth Management & Business Banking
  • 1984-1994 Jelmoli SA, Projectleader and Product Management
Alexandra  Keller
Alexandra Keller, Office Manager/Assistant
  • Since 2015 at Bellevue Asset Management
  • 2012-2015 at Adamant Biomedical Investments AG
  • Commercial employee with federal diploma in Banking
  • Cyrill  Zimmermann
  • Oliver Kubli
  • Remo Krauer
  • Samuel Stursberg
  • Christian Lach
  • Hanns Frohnmeyer
  • Stefan  Blum
  • Marcel  Fritsch
  • Marvin Ng
  • Michael  Mullen
  • Zahide Donat
  • Sandra Muino
  • Christina Wirz
  • Alexandra  Keller

Team BB Healthcare Trust plc

Paul Major
Paul Major, Portfolio Manager
  • Since 2016 Portfolio Manager BB Healtcare Trust plc
  • 2004-2016 Research Partner at Redburn
  • 1996-2003 Analyst and Corporate Financier at UBS Warburg
  • Master in Biochemistry (University of Bath)
Brett Darke
Brett Darke, CFA, Portfolio Manager
  • Since 2017 member of the Investment Team BB Healthcare Trust plc
  • 2006 – 2017 Analyst life sciences and healthcare sector at TT International for long-only and long/short funds.
  • 2001 – 2006 Corporate finance at Merrill Lynch and Bear Stearns
  • Masters degree in Medicine and Management studies from Cambridge University
  • CFA Charterholder
  • Paul Major
  • Brett Darke

Our investment solutions

Bellevue Asset Management’s range of healthcare sector investment products is the broadest in Europe and, with the investment company BB Biotech, it has been an active and widely recognized investor in this sector for more than 20 years. The Healthcare Index created by Adamant in 2007 reflects the findings of its fundamental research. It is composed of the 40 most attractive healthcare stocks worldwide and is recalibrated every six months.

Product Date ISIN NO. NAV YTD 1YR 3YR Factsheet

BB Adamant Healthcare Strategy (Lux)

> I-USD 28.05.2020 LU1477742818 210.55 4.97% 18.78% 40.48%
  • EN

    • DE
    • EN
> B-EUR 28.05.2020 LU1477743386 203.42 6.29% 19.22% 39.04%
  • EN

    • DE
    • EN
> B-CHF 28.05.2020 LU1477743113 200.34 4.38% 12.91% 36.23%
  • EN

    • DE
    • EN
> B-USD 28.05.2020 LU1477742909 205.18 4.68% 17.96% 37.46%
  • EN

    • DE
    • EN
> I-CHF 28.05.2020 LU1477743030 205.60 4.68% 13.70% 39.24%
  • EN

    • DE
    • EN
> I-EUR 28.05.2020 LU1477743204 208.77 6.58% 20.05% 42.12%
  • EN

    • DE
    • EN
> I2-CHF 28.05.2020 LU1587979250 186.19 4.79% 13.98% 40.15%
  • EN

    • DE
    • EN
> I2-USD 28.05.2020 LU1587979177 192.98 5.08% 19.07% 41.40%
  • EN

    • DE
    • EN
> I2-EUR 28.05.2020 LU1587979334 186.70 6.69% 20.34% 43.04%
  • EN

    • DE
    • EN

Show all share classes

BB Healthcare Trust plc

> BB Healthcare Trust (LSE)-GBP 28.05.2020 GB00BZCNLL95 162.50 16.39% 21.03% 57.36%
  • EN

    • DE
    • EN

BB Adamant Sustainable Healthcare (Lux)

> I-USD 28.05.2020 LU1819585370 147.24 7.36% 20.09% n.a.
  • EN

    • DE
    • EN
> AI2-EUR 28.05.2020 LU1916264432 152.64 9.08% 21.61% n.a.
  • EN

    • DE
    • EN
> B-EUR 28.05.2020 LU1819586261 153.43 8.70% 20.53% n.a.
  • EN

    • DE
    • EN
> B-USD 28.05.2020 LU1819585537 145.29 7.06% 19.26% n.a.
  • EN

    • DE
    • EN
> B-CHF 28.05.2020 LU1819585883 141.29 6.75% 14.15% n.a.
  • EN

    • DE
    • EN
> I-EUR 28.05.2020 LU1819586006 155.50 9.01% 21.38% n.a.
  • EN

    • DE
    • EN
> I-CHF 28.05.2020 LU1819585610 143.19 7.07% 14.96% n.a.
  • EN

    • DE
    • EN
> I2-EUR 28.05.2020 LU1819586188 156.09 9.09% 21.63% n.a.
  • EN

    • DE
    • EN
> I2-USD 28.05.2020 LU1819585453 147.79 7.44% 20.33% n.a.
  • EN

    • DE
    • EN
> I2-CHF 28.05.2020 LU1819585701 143.74 7.14% 15.19% n.a.
  • EN

    • DE
    • EN

Show all share classes

News

Markets & Opinions / 27.05.2020

Recording of the update call with Portfolio Manager Zahide Donat on May 27.

Markets & Opinions / 27.05.2020

Commentary by Stefan Blum and Marcel Fritsch, Portfolio Managers of the BB Adamant Medtech & Services Fund

Markets & Opinions / 26.05.2020

Read the current issue with focus on the corona virus. 

Markets & Opinions / 19.05.2020

Recording of the update call with Portfolio Manager Stefan Blum on May 19.

Markets & Opinions / 06.05.2020

Recording of the update call with portfolio manager Stefan Blum on May 6.

Markets & Opinions / 06.05.2020

Commentary on the Asian healthcare market by the Portfolio Managers Oliver Kubli and Remo Krauer.

Markets & Opinions / 29.04.2020

Recording of the update call with Dr. Cyrill Zimmermann, Head Healthcare Funds & Mandates, on April 29.

Markets & Opinions / 16.04.2020

BB Adamant Medtech & Services Fund earned an award as best European fund in the Health category.

Markets & Opinions / 16.04.2020

Market commentary by Stefan Blum, Portfolio Manager BB Adamant Medtech & Services. 

Markets & Opinions / 15.04.2020

Recording of the update call with the portfolio manager Oliver Kubli and Remo Krauer on April 15, 2020.